logo-loader
NASDAQ:ZYNE

Zynerba Pharmaceuticals

Recieve alerts
Market:
NASDAQ
Market Cap:
$259.82 m
Price
0.00
Change
0.58%
52 weeks high
16.46
52 weeks low
2.82
;

Viewing results 1-25 of 29

Zynerba boosts cash position in 2Q, gears up for top-line data from key trials with Zygel CBD gel

The company has a cash pile of $88.7 million to fund operations and reach clinical milestones in the first half of 2020...

1 week, 6 days ago

Zynerba Pharmaceuticals joins Russell 3000 and Russell 2000 indexes

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies...

on 1/7/19

Zynerba wins new US patent for treatment of Autism Spectrum Disorder with CBD

The patent comes at an opportune times as enrollment speeds up in Zynerba’s open label Phase 2 BRIGHT study evaluating the safety, and potency of its Zygel CBD gel ...

on 11/6/19

Zynerba tells FDA it should regulate CBD and cannabis-derived products like standard pharmaceuticals

The FDA is holding its first public hearing on how it should regulate cannabis and CBD, and the agency asked Zynerba and others involved with the plant to comment ...

on 31/5/19

Zynerba launches the Phase 2 trial of its Zygel CBD gel to treat 22q genetic condition

The disorder is caused by a small missing piece of the 22nd chromosome that can affect every system in the body...

on 29/5/19

Zynerba boosts cash position in 1Q, gears up for top-line data from four key trials with Zygel CBD gel

The company has a cash pile of $68.3 million to fund operations and reach clinical milestones in the first half of 2020...

on 8/5/19

Zynerba Pharmaceuticals scores Fast Track FDA designation for Zygel CBD gel

US regulators have awarded the distinction to expedite the development of the drug to treat Fragile X syndrome...

on 6/5/19

Zynerba rockets as investors await CEO's presentation at London conference

The 2019 HC Wainwright Global Life Sciences Conference will take place on April 9 at the Grosvenor House...

on 3/4/19

Zynerba’s 4Q shows momentum as it heads into key clinical trial

CEO Armando Anido says the company’s strong cash position is expected to take it through its NDA submission and potential approval for Zygel in Fragile X syndrome...

on 11/3/19

Zynerba Pharmaceuticals launches Phase 2 trial of Zygel in autism spectrum disorder

The Pennsylvania-based company which is doing trail-blazing work pushing clinical trials for cannabis-derived treatments, expects to present top-line data from the study in the first half of 2020...

on 7/3/19

Zynerba Pharmaceuticals receives new US patent for treatment of Fragile X syndrome with CBD

The new patent which expires in 2038, is part of an expanding intellectual property portfolio covering Zynerba’s flagship ZYN002 synthetic CBD gel...

on 26/2/19

Zynerba Pharmaceuticals’ quest for CBD gel to treat Fragile X syndrome ventures where big pharma fears to tread

With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals ...

on 22/2/19

Zynerba Pharmaceuticals adds pharma exec to its board

Pamela Stephenson brings expertise in commercial planning to the developer of transdermal cannabinoid therapies ...

on 20/2/19

Proactive Investors cannabis conference in New York showcases industry potential for investors

More than 100 attendees heard updates from Alchemist, ICOX Innovations, Pharmalogyx, Pressure BioSciences and Zynerba Pharmaceuticals...

on 31/1/19

Proactive Investors conference in New York focuses on small-cap cannabis industry

Participating companies are Alchemist Inc, ICOX Innovations, Pharmalogyx, Pressure BioSciences and Zynerba Pharmaceuticals ...

on 30/1/19

Zynerba Pharmaceuticals stock soars amid slew of positive drivers

Mad Money host Jim Cramer said he expects 'marijuana-adjacent' biotechnology companies to start getting more credit from investors for their cannabis-influenced businesses...

on 30/1/19

SCYNEXIS names Zynerba CEO Armando Anido to its board

Anido boasts more than 30 years of experience in the biopharmaceutical sector...

on 22/1/19

Zynerba on track to report cannabidiol gel treatment results for Fragile X childhood disorder

The company has completed enrollment for its Phase 2 clinical trial of the gel's use with children and adolescents with developmental and epileptic encephalopathy...

on 19/12/18

Zynerba Pharmaceuticals CEO welcomes FDA approval of cannabinoid products

The treatment Zynberba is developing is for Fragile X Syndrome, the leading known genetic cause of both inherited intellectual disability and autism spectrum disorder...

on 5/11/18

Are marijuana stocks too high for an investor tempted to join the party, or do they have room to run?

Cronos stock recovers on Friday after saner voices intervened and defended the Canadian cannabis stock from a classic short-selling attack...

on 3/9/18

Daily CryptoCann Report: Buy a classic car with crypto; WeedMD inks distribution deal in Alberta

Custom car builder Classic Recreations will now accept Bitcoin and other digital currencies as payment...

on 5/7/18

Zynerba Pharmaceuticals shares sink after unsuccessful trial of cannabis-based skin patch

The company will shift its focus to ZYN002, a treatment for epilepsy...

on 5/7/18